DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
12755637
DOI
10.1021/bi0342315
Knihovny.cz E-resources
- MeSH
- DNA Adducts MeSH
- Cell-Free System MeSH
- Cisplatin analogs & derivatives chemistry metabolism pharmacology MeSH
- Nucleic Acid Denaturation drug effects MeSH
- DNA chemistry genetics metabolism MeSH
- Kinetics MeSH
- Humans MeSH
- Tumor Cells, Cultured MeSH
- Organoplatinum Compounds chemistry metabolism pharmacology MeSH
- Antineoplastic Agents chemistry metabolism pharmacology MeSH
- Cross-Linking Reagents MeSH
- Base Sequence MeSH
- Cattle MeSH
- Stereoisomerism MeSH
- In Vitro Techniques MeSH
- Binding Sites MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Cattle MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- DNA Adducts MeSH
- Cisplatin MeSH
- DNA MeSH
- Organoplatinum Compounds MeSH
- Antineoplastic Agents MeSH
- Cross-Linking Reagents MeSH
- transplatin MeSH Browser
The global modification of mammalian and plasmid DNAs by novel platinum compounds, cis- or trans-[PtCl(2)(NH(3))(Am)], where Am = NH(3), nonplanar heterocycle piperidine, piperazine, or aromatic planar heterocycle 4-picoline, was investigated in cell-free media using various biochemical and biophysical methods. These modifications have been compared with the activity of these new compounds in several tumor cell lines including those resistant to antitumor cis-diamminedichloroplatinum(II) (cisplatin). The results show that the replacement of the NH(3) group in cisplatin by the heterocyclic ligands does not considerably affect the DNA binding mode of this drug. Cytotoxicity studies have revealed that the replacement lowers the activity of the platinum compound in both sensitive and resistant cell lines. It has been suggested that the reduced activity of these analogues of cisplatin is associated with some features of the damaged DNA and/or its cellular processing. Alternatively, the reduced activity of the analogues of cisplatin might also be due to the factors that do not operate directly at the level of the target DNA, such as intracellular platinum uptake. In contrast to the analogues of cisplatin, the replacement of one ammine group by the heterocyclic ligand in its clinically ineffective trans isomer (transplatin) results in a radical enhancement of its activity in tumor cell lines. Importantly, this replacement also markedly alters the DNA binding mode of transplatin. The results support the view that one strategy of how to activate the trans geometry in bifunctional platinum(II) compounds including circumvention of resistance to cisplatin may consist of a chemical modification of the ineffective transplatin that results in an increased stability of its intrastrand cross-links in double-helical DNA and/or in an increased efficiency to form interstrand cross-links.
References provided by Crossref.org
Can Satraplatin be hydrated before the reduction process occurs? The DFT computational study
Biophysical studies on the stability of DNA intrastrand cross-links of transplatin
